Patent Term Extension U.S. vs. EU SPC vs. Japan: The Complete Strategic Guide for Pharma IP Teams
Pharma IP teams dont lose patentsthey lose time. And in 2026, time is the most valuable asset on the balance sheet.
A new strategic guide from DrugPatentWatch breaks down a question that sounds technicalbut decides market exclusivity, launch sequencing…
